Mankind Pharma is currently trading at Rs. 2310.35, up by 11.85 points or 0.52% from its previous closing of Rs. 2298.50 on the BSE.
The scrip opened at Rs. 2339.60 and has touched a high and low of Rs. 2339.60 and Rs. 2287.00 respectively. So far 4148 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 2726.75 on 15-Jul-2025 and a 52 week low of Rs. 1909.90 on 23-Mar-2026.
Last one week high and low of the scrip stood at Rs. 2,640.00 and Rs. 2,239.20 respectively. The current market cap of the company is Rs. 94983.57 crore.
The promoters holding in the company stood at 72.66%, while Institutions and Non-Institutions held 24.66% and 2.68% respectively.
Mankind Pharma’s wholly owned subsidiary (WOS) -- Mankind Lifesciences (MLS) has acquired the remaining 10% stake of Upakarma Ayurveda (Upakarma) from Kaushcorp Media LLP through a share purchase agreement (SPA) for Rs 75 lakh (payable in two tranches as per SPA) on June 2, 2026. MLS is already holding 90% stake in Upakarma.
This acquisition will enable the company to achieve better operational efficiencies through streamlined processes. Consequent to this acquisition, Upakarma has become a WOS of MLS and a step-down WOS of the company.
Mankind Pharma is engaged in developing, manufacturing and marketing a diverse range of pharmaceutical formulations across various acute and chronic therapeutic areas, as well as several consumer healthcare products.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1783.55 |
| Dr. Reddys Lab | 1277.80 |
| Cipla | 1400.70 |
| Zydus Lifesciences | 1088.90 |
| Lupin | 2268.10 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: